↓ Skip to main content

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

Overview of attention for article published in The Lancet, March 2017
Altmetric Badge
565

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news
56 news outlets
blogs
1 blog
policy
1 policy source
twitter
188 tweeters
facebook
6 Facebook pages

Citations

dimensions_citation
418 Dimensions

Readers on

mendeley
418 Mendeley